Literature DB >> 12049187

Relationship between serum complement and different lipid disorders.

A L Pasqui1, L Puccetti, G Bova, M Di Renzo, F Bruni, M Pastorelli, A Palazzuoli, A Auteri.   

Abstract

Inflammatory and lipid factors share an important role in atherosclerosis. Recent studies showed the concomitant presence and increase of complement components and lipids both in the atherosclerotic plaque and the circulating blood. The aim of this study was to examine the relationship between the complement system and lipid disorders. We evaluated the circulating complement terminal complex C5b-9, a clear sign of complement activation, in three groups of 30 patients the first with hypercholesterolemia, the second with hypertriglyceridemia (associated with low values of HDL-cholesterol), the third with low levels of HDL-cholesterol compared with an equivalent group of matched normolipemic subjects. We found a significant increase of sC5b-9 in each group of patients compared with controls. The mean sC5b-9 level in the hypercholesterolemic population was 366.2 +/- 141.2 ng/ml (P<0.01), 395.4 +/- 118.2 ng/ml in the hypertrygliceridemic group (P<0.01), 414.8 +/- 126.4 ng/ml in the low HDL-chol subjects (P<0.01), and 182.0 +/- 40.8. ng/ml in the control group. Regression analysis showed a significant direct correlation between sC5b-9 and triglycerides (r=0.64), and a significant inverse correlation between sC5b-9, HDL-chol (r=-0.74), and apo-A1 (r=-0.68); no significant relationship was found between sC5b-9 and cholesterol. We suggest that complement activation is associated with the various lipid disorders and is more important in those dyslipidemic conditions in which other factors may be involved. In particular, hypertriglyceridemia may be associated with endothelial and fibrinolytic disturbances, and the decrease of HDL may induce the failure of the regulatory proteins transported by the same HDL.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12049187     DOI: 10.1007/s102380200004

Source DB:  PubMed          Journal:  Clin Exp Med        ISSN: 1591-8890            Impact factor:   3.984


  5 in total

Review 1.  Current and future therapies for addressing the effects of inflammation on HDL cholesterol metabolism.

Authors:  Fatima Iqbal; Wendy S Baker; Madiha I Khan; Shwetha Thukuntla; Kevin H McKinney; Nicola Abate; Demidmaa Tuvdendorj
Journal:  Br J Pharmacol       Date:  2017-03-23       Impact factor: 8.739

2.  High-density lipoproteins and the immune system.

Authors:  Hidesuke Kaji
Journal:  J Lipids       Date:  2013-01-30

Review 3.  High-Density Lipoproteins as Homeostatic Nanoparticles of Blood Plasma.

Authors:  Vasily A Kudinov; Olga Yu Alekseeva; Tatiana I Torkhovskaya; Konstantin K Baskaev; Rafael I Artyushev; Irina N Saburina; Sergey S Markin
Journal:  Int J Mol Sci       Date:  2020-11-19       Impact factor: 5.923

4.  Antirheumatic therapy is associated with reduced complement activation in rheumatoid arthritis.

Authors:  Thao H P Nguyen; Ingrid Hokstad; Morten Wang Fagerland; Tom Eirik Mollnes; Ivana Hollan; Mark W Feinberg; Gunnbjørg Hjeltnes; Gro Ø Eilertsen; Knut Mikkelsen; Stefan Agewall
Journal:  PLoS One       Date:  2022-02-25       Impact factor: 3.240

Review 5.  Dysfunctional High-Density Lipoprotein: An Innovative Target for Proteomics and Lipidomics.

Authors:  Juan Salazar; Luis Carlos Olivar; Eduardo Ramos; Mervin Chávez-Castillo; Joselyn Rojas; Valmore Bermúdez
Journal:  Cholesterol       Date:  2015-11-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.